35Pharma Oral Presentation at ObesityWeek 2025: HS235 Demonstrates Activity in Pre-Clinical Models of Obesity and Heart Failure

35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today presented pre-clinical HS235 data during an oral presentation at ObesityWeek 2025 in Atlanta, GA.

HS235 is a next-generation BMP-9/-10 sparing Activin Signaling Inhibitor being investigated in patients with pulmonary hypertension. HS235 was engineered to achieve higher potency against Activin and Growth Differentiation Factor ligands while sparing BMP-9/-10 ligands whose neutralization has been associated with bleeding, telangiectasia and pericardial effusions.

During the oral presentation, Maureen O’Connor, Ph.D., Chief Scientific Officer of 35Pharma, presented pre-clinical data demonstrating that HS235 effectively addresses major hallmarks of HFpEF by:

• Selectively decreasing fat mass, including pericardial adipose tissue;
• Improving the synthesis of adipokines yielding a metabolically more favourable profile; and
• Reversing cardiac hypertrophy and rescuing left ventricular function.

Collectively, these data support HS235’s differentiated profile and potential to address both cardio-pulmonary remodeling as well as metabolic dysfunction. Two Phase 1b clinical trials have been initiated to evaluate HS235 in patients with obesity and Pulmonary Hypertension due to HFpEF (PH-HFpEF, Group 2 PH) and patients with Pulmonary Arterial Hypertension (PAH, Group 1 PH).

‍